Hsbc Holdings PLC Has $640,000 Stock Holdings in Silence Therapeutics PLC Sponsored ADR $SLN

Hsbc Holdings PLC trimmed its position in Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) by 28.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 122,834 shares of the company’s stock after selling 50,000 shares during the quarter. Hsbc Holdings PLC owned 0.26% of Silence Therapeutics worth $640,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Boothbay Fund Management LLC boosted its holdings in shares of Silence Therapeutics by 1.0% in the 2nd quarter. Boothbay Fund Management LLC now owns 252,421 shares of the company’s stock valued at $1,464,000 after purchasing an additional 2,409 shares in the last quarter. Two Sigma Investments LP raised its holdings in shares of Silence Therapeutics by 6.6% during the 3rd quarter. Two Sigma Investments LP now owns 63,247 shares of the company’s stock worth $328,000 after buying an additional 3,935 shares in the last quarter. ADAR1 Capital Management LLC lifted its position in shares of Silence Therapeutics by 26.8% during the 4th quarter. ADAR1 Capital Management LLC now owns 23,643 shares of the company’s stock worth $144,000 after buying an additional 5,000 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Silence Therapeutics by 65.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,653 shares of the company’s stock valued at $83,000 after buying an additional 5,421 shares in the last quarter. Finally, Bank of Montreal Can grew its position in Silence Therapeutics by 4.4% in the fourth quarter. Bank of Montreal Can now owns 160,474 shares of the company’s stock valued at $976,000 after acquiring an additional 6,692 shares during the last quarter. 98.73% of the stock is currently owned by institutional investors.

Silence Therapeutics Stock Up 0.6%

Shares of SLN opened at $11.62 on Friday. Silence Therapeutics PLC Sponsored ADR has a 12-month low of $4.19 and a 12-month high of $12.19. The business has a 50-day simple moving average of $8.76 and a two-hundred day simple moving average of $6.94. The stock has a market cap of $548.93 million, a PE ratio of -7.31 and a beta of 1.38.

Silence Therapeutics (NASDAQ:SLN) last posted its earnings results on Friday, May 8th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.14). The firm had revenue of $0.42 million during the quarter, compared to the consensus estimate of $1.25 million. Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 105.34%. On average, equities research analysts expect that Silence Therapeutics PLC Sponsored ADR will post -1.08 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on SLN shares. HC Wainwright reissued a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a report on Wednesday, June 17th. Cantor Fitzgerald started coverage on shares of Silence Therapeutics in a report on Wednesday, June 24th. They set an “overweight” rating on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $55.00.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.